active antiretroviral Therapy
Introduction
In active antiretroviral Therapy, Ritonavir is common structural information from proteins and used to develop drug .Antiretroviral used togetherwith other medication to treat HIV .It can be sold inform of soft gelatin capsule or else in heat stable tablet dosage. This drug isnot alcoholsoluble with water and oleic acid is used solubilize this Ritonavir drug. If in tablet the drug for this appear in polymer melt dispersion technology is applied.
Ritonavir together with other drugs may result to serious life effects. So it is advisable for a patient to inform the doctor if he is taking some medications such as dihydroergotamine, ergotamine and sleeping pills. This lowers the chances of one to suffer from side effects of this medication.
This drug is classified in protease inhibitors .As noted earlier it is used together with other drugs to lower the amount of Human Immune Syndrome in one’s blood. It true that this drug does not cure but HIV, it minimizes the probability on one getting AIDs and any other infection related to HIV.Like any other drug Ritonavir causes side effects which can be serious. They include blistering of the skin, stomach pain, yellowing of skins and irregular heartbeat. Types of Antiretroviral Drugs used in HIV/AIDS Clinical Management
There are different components of antiretroviral drugs they are including nucleoside reverse transcriptase inhibitors (NRTIs), The Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Protease inhibitor (PIs), Fusion inhibitors, Integrase inhibitors, Entry inhibitors and Maturation inhibitors.
In conclusion it Ritonavir drugs are very important drugs .They are decreasing the rob ability of getting HIV infection and this will increase the chances healthy life. I think it is important to use this medication as prescribed by the doctors and this will generally increase peoples life expectancy. Peoples should also be aware of the side effects this drug .
Work cited
Samant, Lalit R., et al. “In silico molecular interactions of HIV antiviral drugs against HPV type 18 E6 protein.” World J Pharm Pharm Sci 4 (2015): 1056-1066.
Iqbal, M., et al. “Placental drug transporters and their role in fetal protection.” Placenta 33.3 (2012): 137-142.
Dalvie, Deepak. “Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics.” Current pharmaceutical design 6.10 (2000): 1009-1028.